A Canadian naturalistic study of a community-based cohort treated for bipolar disorder

Sagman, Doron; Lee, Bobbie; Chandresena, Ranjith; Jones, Barry; ^runner, Elizabeth
January 2010
BMC Psychiatry;2010, Vol. 10, p24
Academic Journal
Background: Bipolar illness is associated with significant psychosocial morbidity and health resource utilization. Second generation antipsychotics, used alone or in combination with mood stabilizers are effective in treating acute mania in community settings. This study was designed to compare the change in clinical parameters and resource utilization at one month in a group of patients who required treatment intervention for exacerbation of mania. The clinical response at one year was also evaluated. Methods: 496 patients were enrolled at 75 psychiatric practices across Canada. The Olanzapine cohort (n = 287) included patients who had olanzapine added to their medication regimen or the dose of olanzapine increased. The Other cohort (n = 209) had a medication other than olanzapine added or the dose adjusted. Changes from baseline in the Young Mania Rating Scale (YMRS), Montgomery Asberg Depression Rating Scale, Beck Anxiety Inventory and SF-12 Health Survey were compared at one month using ANCOVA. Categorical variables at one month for health resource utilization, employment status, abuse/dependency, and the number of suicide attempts were compared using Fisher's Exact test. Patients were followed for one year and a subgroup was evaluated. Results: At one month, patients in the Olanzapine cohort recorded a mean reduction in the YMRS of 11.5, significantly greater than the mean reduction in the Other cohort of 9.7 (ANCOVA P = 0.002). The Olanzapine cohort was significantly improved compared to the Other cohort on the scales for depression and anxiety and did not experience the deterioration in physical functioning seen in the Other cohort. No significant differences were detected in health-related quality-of-life measures, employment status, drug abuse/dependency, number of suicide attempts, mental functioning, emergency room visits or inpatient psychiatric hospitalizations. In a subgroup treated for 12 months with a single second generation antipsychotic, improvements in illness severity measures were maintained with no evidence of significant differences among the antipsychotics. Conclusions: Patients with bipolar disorder requiring treatment intervention for exacerbation of mania in the community setting responded to olanzapine at one month. In a subset analysis, second generation antipsychotic treatment continued to be beneficial in reducing bipolar symptoms at one year.


Related Articles

  • Psychiatric comorbidities in patients with major depressive disorder. Thaipisuttikul, Papan; Ittasakul, Pichai; Waleeprakhon, Punjaporn; Wisajun, Pattarabhorn; Jullagate, Sudawan // Neuropsychiatric Disease & Treatment;2014, Vol. 10, p2097 

    Background: Psychiatric comorbidities are common in major depressive disorder (MDD). They may worsen outcome and cause economic burden. The primary objective was to examine the prevalence of psychiatric comorbidities in MDD. The secondary objectives were to compare the presence of comorbidities...

  • Breaking News: New Gene for Bipolar Discovered.  // Bioscience Technology;2014, p1 

    The article presents a research study on the discovery of new genes for bipolar. Topics discussed include the connection of two newly found gene regions with bipolar disorder which is also called manic-depressive disorder, emotional ups and downs in bipolar patients, and the genetic factors...

  • Neurocognitive profiles in treatment-resistant bipolar I and bipolar II disorder depression. Kessler, Ute; Schoeyen, Helle K.; Andreassen, Ole A.; Eide, Geir E.; Hammar, Åsa; Malt, Ulrik F.; Oedegaard, Ketil J.; Morken, Gunnar; Sundet, Kjetil; Vaaler, Arne E. // BMC Psychiatry;2013, Vol. 13 Issue 1, p1 

    Background: The literature on the neuropsychological profiles in Bipolar disorder (BD) depression is sparse. The aims of the study were to assess the neurocognitive profiles in treatment-resistant, acutely admitted BD depression inpatients, to compare the neurocognitive functioning in patients...

  • Managing Every Shade Of Blue. Miller, Michael Craig // Newsweek;Summer2005 Special Edition, Vol. 145 Issue 26A, p34 

    Reports on the efforts to treat the varying degrees of depression. Example of how the same medication can have benefits for one patient and not another; Efforts to target drugs more effectively; Examination of DNA sequences of patients suffering from depression; How biology makes certain people...

  • q1Bipolar spectrum features in drug resistant unipolar depression patients: TRES-DEP pilot study. Dudek, Dominika; Siwek, Marcin; Borowiecka-Kluza, Joanna; Pawłowski, Tomasz; Kiejna, Andrzej; Łojko, Dorota; Rybakowski, Janusz K. // Archives of Psychiatry & Psychotherapy;Jun2009, Vol. 11 Issue 2, p65 

    Aim. The aim this pilot study of the all-Polish multicenter TRES-DEP (Treatment Resistant Depression) project was the detection and analysis of bipolar spectrum features in drug-resistant (DR) patients with unipolar depression in comparison with patients who responded to standard antidepressant...

  • DSM-IV Depression with Atypical Features: Is It Valid? Stewart, Jonathan W.; McGrath, Patrick J.; Quitkin, Frederic M.; Klein, Donald F. // Neuropsychopharmacology;Dec2009, Vol. 34 Issue 13, p2625 

    Atypical features were incorporated into the American Psychiatric Association's Diagnostic and Statistical Manual, Fourth Edition (DSM-IV, 1994) as an illness specifier for major depression and dysthymia. The validity of depression with atypical features was supported by differences relative to...

  • Rapid-cycling bipolar disorder: cross-national community study. Lee, Sing; Tsang, Adley; Kessler, Ronald C.; Jin, Robert; Sampson, Nancy; Andrade, Laura; Karam, Elie G.; Mora, Maria Elena Medina; Merikangas, Kathleen; Nakane, Yoshibumi; Popovici, Daniela Georgeta; Posada-Villa, Jose; Sagar, Rajesh; Wells, J. Elisabeth; Zarkov, Zahari; Petukhova, Maria // British Journal of Psychiatry;Mar2010, Vol. 196 Issue 3, p217 

    Background: The epidemiology of rapid-cycling bipolar disorder in the community is largely unknown.Aims: To investigate the epidemiological characteristics of rapid-cycling and non-rapid-cycling bipolar disorder in a large cross-national community sample.Method:...

  • Optimizing depression, bipolar therapy: Much work remains. Wolfe, Kelly // Pharmacy Today;May2006, Vol. 12 Issue 5, p8 

    The article presents insight into the nature and treatment of depression and bipolar disorder. New information about antidepressive use is documented in recent studies, however, the findings support a plethora of choices for the real-world treatment of depression. The Sequenced Treatment...

  • Validation of the Chinese version of the "Mood Disorder Questionnaire" for screening bipolar disorder among patients with a current depressive episode.  // BMC Psychiatry;2012, Vol. 12 Issue 1, p8 

    The article focuses on the study which measures the accuracy of the Mood Disorder Questionnaire (MDQ) as a screening instrument for bipolar disorder (BPD) in patients suffering from current major depressive episode. It informs that several methods were done to evaluate the performance of MDQ and...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics